Non-inferiority studies efficacy and safety: review of methodological and statistical aspects in clinical trials and non-interventional studies with medicinal products.
e202209074
Keywords:
Methodology, Review, Clinical trials, Observational studiesAbstract
Non-inferiority studies are increasingly more common for introducing new medicines in the market. Despite being situations where the use of this study design is justified, there is not a common analytical approach on how to conduct them. Pursuing a rigorous methodology, both in the study conduction and in its disseminations, is critical to ensure robust results to enable regulatory agencies and clinicians to reach valid conclusions and decisions which ultimately will benefit clinical practice. Most of the published reviews focus on the efficacy outcomes of non-inferiority clinical trials. We are unaware of other reviews that goes beyond and includes specific aspects for non-interventional designs and for studies focused on safety. Moreover, this review provides a simple and practical perspective with a minimum mathematical content on this complex type of studies.
Downloads
References
European Medicines Agency (EMA). Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol. 2001; 52: 223-228.
Catalá-López F, González-Bermejo D, De la Fuente Honrubia C, Macías Saint-Gerons D. Clinical equipoise and systematic reviews of randomized controlled trials. Med Clin (Barc). 2015; 145 (11): 496-498.
Ebutt AF, Frith L. Practical issues in equivalence trials. Stat. Med. 1998; 17: 1691-1701.
Mauri L, D’Agostino RB Sr. Challenges in the Design and Interpretation of Noninferiority Trials. N Engl J Med. 2017; 377 (14): 1357-1367.
European Medicines Agency (EMA). Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines available. Disponible en https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-need-active-control-therapeutic-areas-where-use-placebo-deemed-ethical-one-more_en.pdf [Citado septiembre de 2022].
Takeda (Shire). A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder. Disponible en https://clinicaltrials.gov/ct2/show/NCT04085172 [Citado septiembre de 2022].
Rothmann M, Lin N, Chen G, Chi GY, Temple R, Tsou HH. Design and analysis of non-inferiority mortality trials in oncology. Stat Med. 2003; 22 (2): 239-264.
Althunian TA, de Boer A, Groenwold RHH, Rengerink KO, Souverein PC, Klungel OH. Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. Pharmacoepidemiol Drug Saf. 2020; 29 (10): 1263-1272.
GlaxoSmithKline. Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study 201038). Disponible en https://www.encepp.eu/encepp/viewResource.htm?id=45347 [Citado septiembre de 2022].
Scott IA. Non-inferiority trials: determining whether alternative treatments are good enough. MJA. 2009; 190 (6): 326-330.
Bland JM, Altman DG. One or two sided tests of significant. BMJ. 1994; 309 (6949): 248.
Department of Health and Human Services. Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness. Guidance for industry. 2016. Disponible en: https://www.fda.gov/media/78504/download [Citado septiembre de 2022].
Estrada Pérez C, Jaimes Barragán F. Ronda clínica y epidemiológica. Estudios de superioridad vs Estudios de no inferoridad. IATREIA. 2014; 27 (1): 117-122.
Head SJ, Kaul S, Bogers AJJC, Kappetein AP. Non-inferiority study design: lessons to be learned from cardiovascular trials. Eur Hear. J. 2012; 33 (11):1318-1324.
Negida A. Sample Size Calculation Guide - Part 6: How to calculate the sample size for a non-inferiority or an equivalence clinical trial. Front Emerg Med. 2019; 4(1): e15.
Molina Arias M. El problema de las comparaciones múltiples. Rev Pediatr Aten Primaria. 2014; 16 (64): 367-370.
McLaughlin MJ, Sainani KL. Bonferroni, Holm and Hochberg corrections: fun names, serious changes to p values. PM R. 2015; 6: 544-546.
Dmitrienko A, Wiens BL, Tamhane AC, Wang X. Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Stat Med. 2007; 26 (12): 2465-2478. doi: http://www.doi.org/10.1002/sim.2716. Erratum in: Stat Med. 2008; 27 (17): 3452.
Brittain E, Lin D. A comparison of intent-to-treat and per protocol results in antibiotic non-inferiority trials. Stat Med. 2005; 24: 1-10.
Westfall PH, Krishen A. Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Stat Plan Infer. 2001; 99: 25-40.
Dmitrienko A, Offen WW, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary endpoints to be significant. Stat Med. 2003; 22: 2400-2403.
European Medicines Agency (EMA). Guideline on the choice on the non-inferiority margin. Disponible en: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-choice-non-inferiority-margin_en.pdf [Citado septiembre de 2022].
Treadwell J, Uhl S, Tipton K, Singh S, Santaguida L, Sun X et al. Assessing equivalence and noninferiority. 2012. Disponible en: https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/equivalence_research.pdf [Citado mayo de 2022].
D´Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: Design concepts and issues. The encounters of academic consultants in statistics. Stat. Med. 2003; 22: 169-186.
Ochiai T, Hamasaki T, Evans SR, Asakura K, Ohno Y. Group sequential three-arm noninferiority clinical trial designs. J Biopharm Stat. 2017; 27(1): 1-24.
Kieser M, Friede T. Planning and analysis of three-arm non-inferiority trials with binary endpoints. Stat Med. 2007; 26 (2): 253-273.
Tang ML, Tang NS. Tests of non-inferiority via rate difference for three arm clinical trials with placebo. J Biopharm Stat. 2004; 14: 337-347.
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME et al. PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26): 2519-2529.
Loli P. Estudios de no-inferioridad en Neurología: tratamientos nuevos, ¿eficacia demostrada? Neurol. Arg. 2010; 2 (1): 42-49.
Cumming G. Replication and p intervals: p values predict the future only vaguely but confidence intervals do much better. Perspect Psycol Sci. 2008; 3 (4): 286-300.
Poole C. Low P-Values or Narrow Confidence Intervals: Which Are More Durable? Epidemiology. 2001; 12 (3): 291-294.
Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Stat Med. 2010; 29 (27): 2769-2780.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Diana González Bermejo, Almudena López-Fando Santafé, Ana Fernández Dueñas, Dolores Montero Corominas, Consuelo Huerta Álvarez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
